ADARx Pharmaceuticals, Inc.

424B4 priced

Price $17.00 · 26,250,000 shares · Gross proceeds $446,250,000

ADARx Pharmaceuticals, Inc. filed a 424B4 registration statement, providing updated financial details and offering information. The company reported $2.9M collaboration revenue in H1 2026 from the AbbVie Agreement, up from $0.2M in H1 2025. R&D expenses increased to $48.3M in H1 2026 compared to $29.965M in H1 2025, driven by expanded therapeutic programs. Liquidity remains strong with $427.3M in cash, cash equivalents, and short-term investments as of June 2026. The filing includes pro forma adjustments for the IPO and private placement, highlighting dilution risks for new investors.

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Price $15.00 · Range $15.00 to $17.00 · 21,875,000 shares

ADARx Pharmaceuticals, Inc. is conducting an IPO with a pro forma capitalization of $503.69 million after the offering and concurrent private placement. The filing highlights significant dilution for new investors, with a pro forma as adjusted net tangible book value of $4.93 per share, resulting in $11.07 per share dilution. The company has $427.25 million in cash, cash equivalents, and short-term investments as of June 30, 2026, and expects to use proceeds to fund operations through 2026. The offering includes conversion of convertible preferred stock to common shares and potential additional shares via underwriter options. The company remains unprofitable, with an accumulated deficit of $269.1 million and no product revenue generated to date.

S-1/A amended

ADARx Pharmaceuticals, Inc. is seeking to raise capital through an IPO, with detailed financial disclosures showing increased research and development expenses, collaboration revenue from AbbVie, and significant liquidity from prior financings. The company remains unprofitable, with expected continued losses as it advances therapeutic candidates through development and seeks regulatory approval. Liquidity is dependent on future funding, and there are risks related to clinical trial outcomes, regulatory approvals, and reliance on collaboration agreements.

S-1 filed

ADARx Pharmaceuticals, Inc. is conducting an IPO with an S-1 filing dated 2026-09-04, replacing a previous DRS/A filing. The offering includes 88,250,216 shares of common stock outstanding as of June 30, 2026, after converting convertible preferred stock into 76,920,354 shares. The filing outlines reserved shares for equity plans (2026 Plan and ESPP) and excludes unexercised options. Pro forma financials show significant net losses, with $48.4 million in six months ended June 30, 2026, and an accumulated deficit of $269.1 million as of that date.

DRS/A amended

ADARx Pharmaceuticals, Inc. reported financial results for Q1 2026 and FY 2025, highlighting significant increases in research and development (R&D) expenses, general and administrative costs, and collaboration revenue under the AbbVie Agreement. The company recognized $2.1M in collaboration revenue for Q1 2026 (vs. $0 in Q1 2025) and $3.4M for FY 2025 (vs. $0 in FY 2024). R&D expenses rose to $23.6M in Q1 2026 (up 83% YoY) and $71.5M in FY 2025 (up 65% YoY), driven by expanded clinical programs. Liquidity remains strong with $455.8M in cash, cash equivalents, and short-term investments as of March 2026, but the company warns of continued operating losses and reliance on future funding.

DRS filed

ADARx Pharmaceuticals, Inc. reported significant increases in operating expenses, particularly in research and development (R&D) and general and administrative costs, driven by expanded clinical programs and collaboration revenue under the AbbVie Agreement. The company recognized $2.1 million in collaboration revenue during Q1 2026, compared to none in Q1 2025, following the May 2025 effective date of the AbbVie Agreement. Net losses widened to $22.7 million in Q1 2026, with liquidity supported by $455.8 million in cash, cash equivalents, and short-term investments as of March 2026. However, the company faces risks related to ongoing losses, reliance on deferred revenue, and substantial future capital needs for clinical development and commercialization.